Management of immune checkpoint inhibitor‐related rheumatic adverse events

Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Clinical Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938753/
https://www.ncbi.nlm.nih.gov/pubmed/31762209
http://dx.doi.org/10.1111/1759-7714.13249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938753/
https://www.ncbi.nlm.nih.gov/pubmed/31762209
http://dx.doi.org/10.1111/1759-7714.13249

Ejemplares similares